Global Submucosal Injectable Composition 麻豆原创 Research Report 2023

Publication ID:

PB501236134

Publication Date:

January 26, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Submucosal Injectable Composition is designed to be used for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions prior to excision with a snare or other endoscopic device.
Highlights
The global Submucosal Injectable Composition market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Submucosal Injectable Composition is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Submucosal Injectable Composition is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Submucosal Injectable Composition include Boston Scientific, The Standard, EndoClot Plus, GI Supply, Cosmo Pharmaceuticals, Ovesco and Seikagaku, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Submucosal Injectable Composition, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Submucosal Injectable Composition.
The Submucosal Injectable Composition market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Submucosal Injectable Composition market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Submucosal Injectable Composition manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Boston Scientific
The Standard
EndoClot Plus
GI Supply
Cosmo Pharmaceuticals
Ovesco
Seikagaku
Segment by Type
Prefilled Syringes
Vial
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Submucosal Injectable Composition manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Submucosal Injectable Composition in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Submucosal Injectable Composition 麻豆原创 Overview
1.1 Product Overview and Scope of Submucosal Injectable Composition
1.2 Submucosal Injectable Composition Segment by Type
1.2.1 Global Submucosal Injectable Composition 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Prefilled Syringes
1.2.3 Vial
1.3 Submucosal Injectable Composition Segment by Application
1.3.1 Global Submucosal Injectable Composition 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Submucosal Injectable Composition 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Submucosal Injectable Composition Revenue 2018-2029
1.4.2 Global Submucosal Injectable Composition Sales 2018-2029
1.4.3 Global Submucosal Injectable Composition 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Submucosal Injectable Composition 麻豆原创 Competition by Manufacturers
2.1 Global Submucosal Injectable Composition Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Submucosal Injectable Composition Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Submucosal Injectable Composition Average Price by Manufacturers (2018-2023)
2.4 Global Submucosal Injectable Composition Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Submucosal Injectable Composition, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Submucosal Injectable Composition, Product Type & Application
2.7 Submucosal Injectable Composition 麻豆原创 Competitive Situation and Trends
2.7.1 Submucosal Injectable Composition 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Submucosal Injectable Composition Players 麻豆原创 Share by Revenue
2.7.3 Global Submucosal Injectable Composition 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Submucosal Injectable Composition Retrospective 麻豆原创 Scenario by Region
3.1 Global Submucosal Injectable Composition 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Submucosal Injectable Composition Global Submucosal Injectable Composition Sales by Region: 2018-2029
3.2.1 Global Submucosal Injectable Composition Sales by Region: 2018-2023
3.2.2 Global Submucosal Injectable Composition Sales by Region: 2024-2029
3.3 Global Submucosal Injectable Composition Global Submucosal Injectable Composition Revenue by Region: 2018-2029
3.3.1 Global Submucosal Injectable Composition Revenue by Region: 2018-2023
3.3.2 Global Submucosal Injectable Composition Revenue by Region: 2024-2029
3.4 North America Submucosal Injectable Composition 麻豆原创 Facts & Figures by Country
3.4.1 North America Submucosal Injectable Composition 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Submucosal Injectable Composition Sales by Country (2018-2029)
3.4.3 North America Submucosal Injectable Composition Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Submucosal Injectable Composition 麻豆原创 Facts & Figures by Country
3.5.1 Europe Submucosal Injectable Composition 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Submucosal Injectable Composition Sales by Country (2018-2029)
3.5.3 Europe Submucosal Injectable Composition Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Submucosal Injectable Composition 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Submucosal Injectable Composition 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Submucosal Injectable Composition Sales by Country (2018-2029)
3.6.3 Asia Pacific Submucosal Injectable Composition Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Submucosal Injectable Composition 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Submucosal Injectable Composition 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Submucosal Injectable Composition Sales by Country (2018-2029)
3.7.3 Latin America Submucosal Injectable Composition Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Submucosal Injectable Composition 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Submucosal Injectable Composition 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Submucosal Injectable Composition Sales by Country (2018-2029)
3.8.3 Middle East and Africa Submucosal Injectable Composition Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Submucosal Injectable Composition Sales by Type (2018-2029)
4.1.1 Global Submucosal Injectable Composition Sales by Type (2018-2023)
4.1.2 Global Submucosal Injectable Composition Sales by Type (2024-2029)
4.1.3 Global Submucosal Injectable Composition Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Submucosal Injectable Composition Revenue by Type (2018-2029)
4.2.1 Global Submucosal Injectable Composition Revenue by Type (2018-2023)
4.2.2 Global Submucosal Injectable Composition Revenue by Type (2024-2029)
4.2.3 Global Submucosal Injectable Composition Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Submucosal Injectable Composition Price by Type (2018-2029)
5 Segment by Application
5.1 Global Submucosal Injectable Composition Sales by Application (2018-2029)
5.1.1 Global Submucosal Injectable Composition Sales by Application (2018-2023)
5.1.2 Global Submucosal Injectable Composition Sales by Application (2024-2029)
5.1.3 Global Submucosal Injectable Composition Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Submucosal Injectable Composition Revenue by Application (2018-2029)
5.2.1 Global Submucosal Injectable Composition Revenue by Application (2018-2023)
5.2.2 Global Submucosal Injectable Composition Revenue by Application (2024-2029)
5.2.3 Global Submucosal Injectable Composition Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Submucosal Injectable Composition Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Boston Scientific
6.1.1 Boston Scientific Corporation Information
6.1.2 Boston Scientific Description and Business Overview
6.1.3 Boston Scientific Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Boston Scientific Submucosal Injectable Composition Product Portfolio
6.1.5 Boston Scientific Recent Developments/Updates
6.2 The Standard
6.2.1 The Standard Corporation Information
6.2.2 The Standard Description and Business Overview
6.2.3 The Standard Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.2.4 The Standard Submucosal Injectable Composition Product Portfolio
6.2.5 The Standard Recent Developments/Updates
6.3 EndoClot Plus
6.3.1 EndoClot Plus Corporation Information
6.3.2 EndoClot Plus Description and Business Overview
6.3.3 EndoClot Plus Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.3.4 EndoClot Plus Submucosal Injectable Composition Product Portfolio
6.3.5 EndoClot Plus Recent Developments/Updates
6.4 GI Supply
6.4.1 GI Supply Corporation Information
6.4.2 GI Supply Description and Business Overview
6.4.3 GI Supply Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GI Supply Submucosal Injectable Composition Product Portfolio
6.4.5 GI Supply Recent Developments/Updates
6.5 Cosmo Pharmaceuticals
6.5.1 Cosmo Pharmaceuticals Corporation Information
6.5.2 Cosmo Pharmaceuticals Description and Business Overview
6.5.3 Cosmo Pharmaceuticals Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Cosmo Pharmaceuticals Submucosal Injectable Composition Product Portfolio
6.5.5 Cosmo Pharmaceuticals Recent Developments/Updates
6.6 Ovesco
6.6.1 Ovesco Corporation Information
6.6.2 Ovesco Description and Business Overview
6.6.3 Ovesco Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Ovesco Submucosal Injectable Composition Product Portfolio
6.6.5 Ovesco Recent Developments/Updates
6.7 Seikagaku
6.6.1 Seikagaku Corporation Information
6.6.2 Seikagaku Description and Business Overview
6.6.3 Seikagaku Submucosal Injectable Composition Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Seikagaku Submucosal Injectable Composition Product Portfolio
6.7.5 Seikagaku Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Submucosal Injectable Composition Industry Chain Analysis
7.2 Submucosal Injectable Composition Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Submucosal Injectable Composition Production Mode & Process
7.4 Submucosal Injectable Composition Sales and 麻豆原创ing
7.4.1 Submucosal Injectable Composition Sales Channels
7.4.2 Submucosal Injectable Composition Distributors
7.5 Submucosal Injectable Composition Customers
8 Submucosal Injectable Composition 麻豆原创 Dynamics
8.1 Submucosal Injectable Composition Industry Trends
8.2 Submucosal Injectable Composition 麻豆原创 Drivers
8.3 Submucosal Injectable Composition 麻豆原创 Challenges
8.4 Submucosal Injectable Composition 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Boston Scientific
The Standard
EndoClot Plus
GI Supply
Cosmo Pharmaceuticals
Ovesco
Seikagaku

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.